Interleukin-15 Therapy for Ischemic Cardiovascular Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches fail to replace myocardial scars or dead neurons with functioning tissue, and there is a need for treatments that can reduce infarct size and improve cardiac function in cardiovascular diseases such as myocardial infarction and stroke.
Innovation Solution
The use of interleukin-15 (IL-15) alone or in combination with agents derived from bone marrow extracts to treat ischemic cardiovascular diseases, including myocardial infarction and stroke, by administering IL-15 to reduce scarring, enhance cardiac remodeling, and increase left ventricular ejection fraction, and by protecting cardiomyocytes and neurons from hypoxia-induced cell death.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic approaches are used, then standard cardiovascular treatment is provided, but myocardial scars and dead neurons cannot be replaced with functioning tissue
Solution Approach 1:
The patent uses bone marrow-derived cells and growth factors (such as VEGF, bFGF, IGF-1) as intermediaries to mediate the regeneration of myocardial tissue and neural tissue. These intermediaries facilitate the transformation of scar tissue into functional tissue by promoting angiogenesis, cell proliferation, and tissue remodeling without directly replacing the damaged tissue themselves.
Solution Approach 2:
The patent employs growth factors and cytokines that induce parameter changes in the damaged tissue environment, such as increasing vascular permeability, modifying extracellular matrix composition, and altering cell differentiation pathways. These parameter changes create conditions favorable for tissue regeneration and functional recovery.
2Reliability
If aggressive therapeutic interventions are applied, then infarct size may be reduced, but treatment complexity and potential side effects increase
Solution Approach 1:
The patent divides the treatment into multiple sequential or combined components: (1) administration of bone marrow-derived cells, (2) delivery of specific growth factors (VEGF, bFGF, IGF-1), and (3) supportive care measures. This segmentation allows for targeted action on different pathological processes while maintaining overall treatment manageability and reducing unnecessary complexity.
3Reliability
If combination therapy with multiple agents is used, then therapeutic efficacy is enhanced, but treatment cost and administration complexity increase
Solution Approach 1:
The patent combines multiple therapeutic agents (bone marrow-derived cells, VEGF, bFGF, IGF-1) into a unified treatment approach where these agents work synergistically. The combination is administered through coordinated protocols that leverage the complementary mechanisms of action of each agent, achieving enhanced cardiac function improvement while managing administration complexity through integrated treatment planning.
Data Source
AI summary
The present disclosure relates generally to the field of cardiovascular diseases. In particular, the present disclosure relates to methods and compositions for treating cardiovascular diseases by administration of a cytokine alone, or in conjunction with other therapeutic agents.